MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Cardiome Pharma Corp Company Profile (NASDAQ:CRME)

Consensus Ratings for Cardiome Pharma Corp (NASDAQ:CRME) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $10.12 (98.18% upside)

Analysts' Ratings History for Cardiome Pharma Corp (NASDAQ:CRME)
Show:
DateFirmActionRatingPrice TargetActions
6/1/2016HC WainwrightInitiated CoverageBuy$9.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016MackieUpgradeHold -> Speculative Buy$5.20 -> $8.60View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/13/2016Canaccord GenuityReiterated RatingBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/14/2015LB SecuritiesReiterated RatingBuy$12.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/19/2014Laurentian Bank of CanadaInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Cardiome Pharma Corp (NASDAQ:CRME)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/13/2016Q116($0.21)($0.06)$6.34 million$7.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q415($0.19)($0.37)$7.74 million$4.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2015Q315($0.23)($0.31)$7.08 million$5.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.25)($0.43)$7.67 million$5.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015Q115($0.28)($0.23)$7.48 million$5.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q414($0.14)($0.39)$8.54 million$7.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2014Q314($0.13)($0.26)$6.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014($0.16)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.11)($0.20)$8.08 million$7.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/27/2014($0.22)($0.53)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2013Q3 13($0.21)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2013Q2 13($0.19)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2013Q113$1.48$1.47$1.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2013Q412($0.05)$0.13$0.84 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2012Q312($0.11)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2011($0.10)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/16/2011($0.11)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2011($0.08)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Cardiome Pharma Corp (NASDAQ:CRME)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.14)($0.13)($0.14)
Q2 20161($0.24)($0.24)($0.24)
Q3 20161($0.25)($0.25)($0.25)
Q4 20161($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)
Dividend History for Cardiome Pharma Corp (NASDAQ:CRME)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Cardiome Pharma Corp (NASDAQ:CRME)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Cardiome Pharma Corp (NASDAQ:CRME)
DateHeadline
06/25/16 07:17 AMWere Analysts Bearish CARDIOME PHARMA CORP (NASDAQ:CRME) This Week? - Engelwood Daily
06/23/16 02:16 PMCardiome Pharma Corporation (CRME) Current Analyst Ratings - Fiscal Standard
06/09/16 09:27 PMCardiome Pharma Corp. (NASDAQ:CRME) Upcoming Earnings: What matter for investors? - iStreetWire
06/08/16 11:35 AMH.C. Wainwright Initiates Coverage on CARDIOME PHARMA CORP to Buy - Trade Calls
06/05/16 11:09 AMAfter Last Week What Do Analysts Think Of Cardiome Pharma Corporation (CRME) - Share Trading News
06/03/16 09:34 PMCardiome Pharma Corporation (NASDAQ:CRME) Stock Update & Estimates - Stock Tick Tock
06/03/16 11:33 AMCardiome Pharma Corporation (NASDAQ:CRME) Set To Release Quarterly Earnings - Investor Newswire
06/02/16 09:27 PMShare Rating Focus on Cardiome Pharma Corporation (NASDAQ:CRME) - HNN - Share Rating Focus on Cardiome Pharma Corporation (NASDAQ:CRME)HNNPresently, Wall Street analysts have given a consensus stock rating of 1.77 on shares of Cardiome Pharma Corporation (NASDAQ:CRME). Covering analysts will typically provide Buy, Sell, or Hold recommendations based on extensive research.and more »
06/01/16 09:33 PMTarget Price and Stock Performance Rundown for Cardiome Pharma Corporation (NASDAQ:CRME) - HNN - Target Price and Stock Performance Rundown for Cardiome Pharma Corporation (NASDAQ:CRME)HNNDuring the latest trading session, Cardiome Pharma Corporation (NASDAQ:CRME) shares traded +3.21%. Monitoring the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent check, shares have been ...and more »
06/01/16 10:51 AMHC Wainwright Begins Coverage on Cardiome Pharma Corp (CRME) - Let Me Know About This - HC Wainwright Begins Coverage on Cardiome Pharma Corp (CRME)Let Me Know About ThisCardiome Pharma Corp logo Analysts at HC Wainwright initiated coverage on shares of Cardiome Pharma Corp (NASDAQ:CRME) in a research note issued to investors on Wednesday. The firm set a “buy” rating and a $9.50 price target on the ...Cardiome Pharma Corporation (NASDAQ:CRME) Hit With "Buy" Rating At H.C. Wainwright, Firm Sees $9.50 Stock PriceFranklin Independentall 5 news articles »
06/01/16 06:28 AMCoverage initiated on Cardiome Pharma by H.C. Wainwright -
05/31/16 03:29 PMRecent Investment Analysts' Ratings Changes for Cardiome Pharma Corp (CRME) - Let Me Know About This - Recent Investment Analysts' Ratings Changes for Cardiome Pharma Corp (CRME)Let Me Know About ThisShares of Cardiome Pharma Corp (NASDAQ:CRME) opened at 4.82 on Tuesday. Cardiome Pharma Corp has a 1-year low of $3.70 and a 1-year high of $10.40. The company has a 50-day moving average of $4.72 and a 200-day moving average of $5.98.
05/27/16 11:57 AMStock Rating Review for Cardiome Pharma Corporation (NASDAQ:CRME) - Wall Street Hints and News - Stock Rating Review for Cardiome Pharma Corporation (NASDAQ:CRME)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 1.77 on shares of Cardiome Pharma Corporation (NASDAQ:CRME). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research.and more »
05/26/16 11:03 AMTarget Check and Stock Performance Recap Cardiome Pharma Corporation (NASDAQ:CRME) - Wall Street Hints and News - Target Check and Stock Performance Recap Cardiome Pharma Corporation (NASDAQ:CRME)Wall Street Hints and NewsIn recent session activity, Cardiome Pharma Corporation (NASDAQ:CRME) shares have traded -0.21%. Monitoring the stock price relative to moving averages may provide enhanced perspective on share performance. After a recent check, the stock has been ...and more »
05/23/16 12:23 PMCardiome Pharma Corp. :CRME-US: Earnings Analysis: Q1, 2016 By the Numbers : May 23, 2016 -
05/23/16 07:25 AMCardiome Pharma (CRME) Jumps: Stock Moves 8.1% Higher -
05/22/16 09:43 PMCardiome Pharma Corporation (CRME) Broker Price Targets For The Coming Week - Share Trading News - Cardiome Pharma Corporation (CRME) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Cardiome Pharma Corporation (CRME). The latest reports which are currently in issue on Sunday 22nd of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy ...Were Analysts Bullish CARDIOME PHARMA CORP (NASDAQ:CRME) This Week?The PostAfter Today's Huge Increase, Is CARDIOME PHARMA CORP's Near-Term Analysis Positive?Franklin Independentall 3 news articles »
05/20/16 11:06 AMAnalyst Rating Check on Cardiome Pharma Corporation (NASDAQ:CRME) - Wall Street Hints and News - Analyst Rating Check on Cardiome Pharma Corporation (NASDAQ:CRME)Wall Street Hints and NewsCurrently, sell-side analysts have provided a consensus stock rating of 1.77 on shares of Cardiome Pharma Corporation (NASDAQ:CRME). Analysts that cover the company will usually offer Buy, Sell, or Hold recommendations based on in-depth research.and more »
05/20/16 11:06 AMRevenue Update on CARDIOME PHARMA CORP(NASDAQ:CRME) - Trade Calls - Revenue Update on CARDIOME PHARMA CORP(NASDAQ:CRME)Trade CallsCARDIOME PHARMA CORP(NASDAQ:CRME) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 13, 2016. Company reported revenue of $7.09M. Analysts estimated a revenue of $6.35M. Earnings ...Latest Analyst Ratings For Cardiome Pharma Corporation (CRME)Share Trading Newsall 2 news articles »
05/19/16 10:01 PMShare Performance and Target Price Review for Cardiome Pharma Corporation (NASDAQ:CRME) - Wall Street Hints and News - Share Performance and Target Price Review for Cardiome Pharma Corporation (NASDAQ:CRME)Wall Street Hints and NewsLooking at stock activity from multiple angles may be of benefit when examining share performance. Investors have the ability to focus in on short or long term share performance. During the most recent trading session, Cardiome Pharma Corporation ...and more »
05/18/16 11:38 AMBroker Outlook For Cardiome Pharma Corporation (CRME) - Share Trading News - Broker Outlook For Cardiome Pharma Corporation (CRME)Share Trading News(Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company's segments are Europe and Rest of World. Cardiome has two marketed, ...
05/16/16 09:25 PMCardiome Pharma Corporation (NASDAQ:CRME) Quarterly EPS Projection At $-0.23 - Investor Newswire - Cardiome Pharma Corporation (NASDAQ:CRME) Quarterly EPS Projection At $-0.23Investor NewswireA week earlier, the EPS projection was $-0.23 while 30-days ago it was $-0.23. This target was set at $-0.23 60 days ago and it was $-0.23 90 days earlier. From a week ago, the change in estimates is 0%. EPS was revised 0 times up and 0 down in last ...
05/15/16 02:24 AMCardiome Pharma's (CRME) CEO Bill Hunter on Q1 2016 Results - Earnings Call Transcript - Welcome to the Cardiome’s 2016 First Quarter Financial Results Conference ... not something every specialty pharma company can say, particularly over the last eight months or so and particularly as we face an uncertain election in the United States.
05/13/16 08:58 AMCardiome Reports First Quarter 2016 Financial Results - [at noodls] - VANCOUVER, May 13, 2016 - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today reported financial results for its first quarter ended March 31, 2016. Amounts, unless specified otherwise, are expressed ...
05/13/16 06:11 AMCardiome reports 1Q loss -
05/13/16 05:19 AMPerformance Recap and Target Perspective on Cardiome Pharma Corporation (NASDAQ:CRME) - Wall Street Hints and News - Performance Recap and Target Perspective on Cardiome Pharma Corporation (NASDAQ:CRME)Wall Street Hints and NewsIn the latest trading session, shares of Cardiome Pharma Corporation (NASDAQ:CRME) moved -0.20%. In order to gain some further insight on stock performance, we can take a look at the stock price relative to some moving averages. After a recent check, ...and more »
05/12/16 02:27 PMCardiome Announces the Launch of ESMOCARD Solution for Injection in France - [at noodls] - Vancouver, Canada, May 12, 2016 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that ESMOCARD (esmolol hydrochloride) 100mg/10ml solution for injection has been commercialized by its ...
05/12/16 05:29 AMCardiome Pharma Corporation: Cardiome to Hold First Quarter 2016 Financial Results Conference Call on May 13 - Vancouver, Canada, May 11, 2016-- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it will report financial results for the first quarter ended March 31, 2016 on the morning of Friday, May 13, 2016. Cardiome will hold a conference call ...
05/11/16 12:47 PMCardiome to Hold First Quarter 2016 Financial Results Conference Call on May 13 - [at noodls] - Vancouver, Canada, May 11, 2016 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it will report financial results for the first quarter ended March 31, 2016 on the morning of Friday, ...
05/11/16 12:47 PMCardiome Announces Publication of Spanish Emergency Department BRINAVESS Study - [at noodls] - Vancouver, Canada, May 11, 2016 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the publication of results from an open label, single-center, single-arm study conducted by independent ...
05/10/16 09:56 PMJennifer Archibald: Rising from the ashes - Jennifer Archibald, CFO at Cardiome Pharma Corp. (Nasdaq:CRME; TSX:COM), was instrumental in guiding the Vancouver-based specialty pharmaceutical company as it rose from the ashes of an aborted deal and rebuilt during a major restructuring. A chartered ...
05/06/16 05:19 AMAverage Analyst Rating for Cardiome Pharma Corporation (NASDAQ:CRME) - B.O.D.Y Confidential - Average Analyst Rating for Cardiome Pharma Corporation (NASDAQ:CRME)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 2 on Cardiome Pharma Corporation (NASDAQ:CRME) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks ...and more »
05/05/16 03:44 PMCardiome and Allergan Announce XYDALBA™ (Dalbavancin) Licensing Agreement in International Markets - [at noodls] - Vancouver, Canada, May 5, 2016 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) announced that its affiliate has signed an exclusive license agreement with an affiliate of Allergan plc that will result ...
05/05/16 03:18 PM4:18 pm Cardiome Pharma & Allergan (AGN) sign exclusive license agreement to commercialize Xydalba in France, the UK, Germany, Belgium, Nordic nations, and certain other European nations along with Canada a -
05/05/16 05:12 AMLatest Analyst Ratings For Cardiome Pharma Corporation (CRME) - Share Trading News - Latest Analyst Ratings For Cardiome Pharma Corporation (CRME)Share Trading NewsCardiome Pharma Corporation has a 50 day moving average of 4.45 and a 200 day moving average of 6.35. The stock's market capitalization is 89.25M, it has a 52-week low of 3.70 and a 52-week high of 10.40. The share price of the company (CRME) was ...
05/01/16 01:39 AMCardiome Pharma Corporation (NASDAQ:CRME) Has An Impact Score Of 0 - RealistInvestor.com - Cardiome Pharma Corporation (NASDAQ:CRME) Has An Impact Score Of 0RealistInvestor.comCardiome Pharma Corporation (NASDAQ:CRME) has been given a 0.56 daily sentiment score for the related articles published on web today. Alpha One offer algorithm-based analytics, which can help state stock sentiment based on the content published on ...and more »
04/30/16 04:02 AMCardiome Pharma Corporation Ord (NASDAQ:CRME) Shorted Shares Decreased By 5.04% - B.O.D.Y Confidential - Cardiome Pharma Corporation Ord (NASDAQ:CRME) Shorted Shares Decreased By 5.04%B.O.D.Y ConfidentialThe stock of Cardiome Pharma Corporation Ord (NASDAQ:CRME) registered a decrease of 5.04% in short interest. CRME's total short interest was 273,400 shares in April as published by FINRA. Its down 5.04% from 287,900 shares, reported previously.and more »
04/28/16 12:20 PMCardiome to Present at the Bloom Burton & Co. 5th Annual Healthcare Investor Conference - [at noodls] - Vancouver, Canada, April 28, 2016 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) announced that David Dean, VP Business Development and Investor Relations of Cardiome, will provide an update on the ...
04/28/16 05:09 AMCardiome Pharma Corporation (NASDAQ:CRME) Analyst Rating Review - The Post - Cardiome Pharma Corporation (NASDAQ:CRME) Analyst Rating ReviewThe PostCovering analysts typically give Buy, Sell and Hold recommendations along with guidance and company earnings projections. Currently, there are 3 analysts that have provided ratings for Cardiome Pharma Corporation (NASDAQ:CRME). 1 have rated the ...and more »
04/28/16 05:09 AMBroker Roundup For Cardiome Pharma Corporation (CRME) - Share Trading News - Broker Roundup For Cardiome Pharma Corporation (CRME)Share Trading News10/14/2013 – Cardiome Pharma Corporation was upgraded to “hold” by analysts at TheStreet. The share price of Cardiome Pharma Corporation (CRME) was up +3.67% during the last trading session, with a day high of 4.58. 34193 shares were traded on ...
04/26/16 08:39 PMCardiome Pharma Corporation (NASDAQ:CRME) Wall Street Rating in Focus - News Tribune - Cardiome Pharma Corporation (NASDAQ:CRME) Wall Street Rating in FocusNews TribuneZacks.com, founded by Len Zacks, a Mathematics Ph.D. from M.I.T. who discovered that earnings estimate revisions are the most powerful force impacting stock prices, track 3 equity research firms that cover shares of Cardiome Pharma Corporation ...and more »
04/26/16 05:29 AMCardiome Pharma Corporation Ord (NASDAQ:CRME) Sellers Covered 7.64% of Their Shorts - The Post - Cardiome Pharma Corporation Ord (NASDAQ:CRME) Sellers Covered 7.64% of Their ShortsThe PostThe stock of Cardiome Pharma Corporation Ord (NASDAQ:CRME) registered a decrease of 7.64% in short interest. CRME's total short interest was 287,900 shares in April as published by FINRA. Its down 7.64% from 311,700 shares, reported previously.Cardiome Pharma Corporation (NASDAQ:CRME): Quarterly EPS Estimate Of $-0.21Investor Newswireall 2 news articles »
04/23/16 05:18 AMHow Many CARDIOME PHARMA CORP (NASDAQ:CRME)'s Analysts Are Bullish? - The Post - How Many CARDIOME PHARMA CORP (NASDAQ:CRME)'s Analysts Are Bullish?The PostOut of 6 analysts covering Cardiome Pharma Corp (NASDAQ:CRME), 5 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 71% are positive. Cardiome Pharma Corp has been the topic of 4 analyst reports since August 11, 2015 according to StockzIntelligence ...
04/23/16 05:18 AMAnalyst Review: Cardiome Pharma Corporation (CRME) - Risers & Fallers - Analyst Review: Cardiome Pharma Corporation (CRME)Risers & FallersA number of investment brokers have recently updated their price targets on shares of Cardiome Pharma Corporation (CRME). According to the latest broker reports outstanding on Friday 22nd of April, 0 analysts have a rating of “strong buy”, 0 analysts ...
04/20/16 05:59 AMCardiome Pharma Corporation (NASDAQ:CRME): Where are Shares Headed? - News Tribune - Cardiome Pharma Corporation (NASDAQ:CRME): Where are Shares Headed?News TribuneResearch analysts covering Cardiome Pharma Corporation (NASDAQ:CRME) shares have provided price target projections on the popular stock. They project that the shares are expected to reach $9.4 within the upcoming year. This consensus number ...
04/19/16 05:45 AMNew Strong Sell Stocks for April 18th - ... Sciences Inc ALIM Avis Budget Group Inc. CAR Bank of America Corp BAC California Water Service Group CWT CARDIOME PHARMA CORP CRME View the entire Zacks Rank #5 List. Want the latest recommendations from Zacks Investment Research? Today, you can ...
04/16/16 09:07 AMCardiome Pharma Corporation Ord (NASDAQ:CRME) Shorted Shares Decreased By 7.64% - RiversideGazette.com - Cardiome Pharma Corporation Ord (NASDAQ:CRME) Shorted Shares Decreased By 7.64%RiversideGazette.comThe stock of Cardiome Pharma Corporation Ord (NASDAQ:CRME) registered a decrease of 7.64% in short interest. CRME's total short interest was 287,900 shares in April as published by FINRA. Its down 7.64% from 311,700 shares, reported previously.and more »
04/15/16 08:52 AMCardiome Pharma Corporation (CRME) Latest Broker Coverage - Risers & Fallers - SmallCapWired.comCardiome Pharma Corporation (CRME) Latest Broker CoverageRisers & FallersA number of investment brokers have recently updated their price targets on shares of Cardiome Pharma Corporation (CRME). According to the latest broker reports outstanding on Friday 15th of April, 0 analysts have a rating of “strong buy”, 0 analysts ...Cardiome Pharma Corp (NASDAQ:CRME) Institutional Investors Sentiment Index Increased in Q3 2015RiversideGazette.comTarget & Performance Rundown Cardiome Pharma Corporation (NASDAQ:CRME)SmallCapWired.comall 3 news articles »
04/13/16 11:05 AMCardiome Pharma Corporation (NASDAQ:CRME) Analyst Recommendation Outlook - Clinton Financial - Cardiome Pharma Corporation (NASDAQ:CRME) Analyst Recommendation OutlookClinton FinancialCovering analysts usually give Buy, Sell and Hold recommendations along with guidance and company earnings estimates. There are 3 analysts providing ratings for Cardiome Pharma Corporation (NASDAQ:CRME). 1 have given the stock a “Strong Buy”, ...and more »
03/29/16 08:07 AMNew Strong Sell Stocks for March 29th -
About Cardiome Pharma Corp

Cardiome Pharma Corp logoCardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company's segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CRME
  • CUSIP:
Key Metrics:
  • Previous Close: $5.11
  • 50 Day Moving Average: $4.9483
  • 200 Day Moving Average: $5.3237
  • P/E Ratio: N/A
  • P/E Growth: -0.2800
  • Market Cap: $103.95M
  • Current Quarter EPS Consensus Estimate: $-0.6400 EPS
Additional Links:
Cardiome Pharma Corp (NASDAQ:CRME) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha